Erickson JW - Search Results

1

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, Ho DD. Markowitz M, et al. Among authors: erickson jw. J Virol. 1995 Feb;69(2):701-6. doi: 10.1128/JVI.69.2.701-706.1995. J Virol. 1995. PMID: 7815532 Free PMC article.

2

Structure-based design of symmetric inhibitors of HIV-1 protease.

Erickson J, Kempf D. Erickson J, et al. Arch Virol Suppl. 1994;9:19-29. doi: 10.1007/978-3-7091-9326-6_3. Arch Virol Suppl. 1994. PMID: 8032250 Review.

3

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.

Ho DD, Toyoshima T, Mo H, Kempf DJ, Norbeck D, Chen CM, Wideburg NE, Burt SK, Erickson JW, Singh MK. Ho DD, et al. Among authors: erickson jw. J Virol. 1994 Mar;68(3):2016-20. doi: 10.1128/JVI.68.3.2016-2020.1994. J Virol. 1994. PMID: 8107264 Free PMC article.

4

Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.

Mo H, Markowitz M, Majer P, Burt SK, Gulnik SV, Suvorov LI, Erickson JW, Ho DD. Mo H, et al. Among authors: erickson jw. AIDS Res Hum Retroviruses. 1996 Jan 1;12(1):55-61. doi: 10.1089/aid.1996.12.55. AIDS Res Hum Retroviruses. 1996. PMID: 8825619

5

In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations.

Kageyama S, Weinstein JN, Shirasaka T, Kempf DJ, Norbeck DW, Plattner JJ, Erickson J, Mitsuya H. Kageyama S, et al. Antimicrob Agents Chemother. 1992 May;36(5):926-33. doi: 10.1128/AAC.36.5.926. Antimicrob Agents Chemother. 1992. PMID: 1510415 Free PMC article.

6

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.

Erickson J, Neidhart DJ, VanDrie J, Kempf DJ, Wang XC, Norbeck DW, Plattner JJ, Rittenhouse JW, Turon M, Wideburg N, et al. Erickson J, et al. Science. 1990 Aug 3;249(4968):527-33. doi: 10.1126/science.2200122. Science. 1990. PMID: 2200122

7

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.

Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, Everitt L, Kempf DJ, Norbeck DW, Erickson JW, Swanstrom R. Kaplan AH, et al. Among authors: erickson jw. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5597-601. doi: 10.1073/pnas.91.12.5597. Proc Natl Acad Sci U S A. 1994. PMID: 8202533 Free PMC article.

8

A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro.

Kageyama S, Hoekzema DT, Murakawa Y, Kojima E, Shirasaka T, Kempf DJ, Norbeck DW, Erickson J, Mitsuya H. Kageyama S, et al. AIDS Res Hum Retroviruses. 1994 Jun;10(6):735-43. doi: 10.1089/aid.1994.10.735. AIDS Res Hum Retroviruses. 1994. PMID: 8074936

9

Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase.

Baldwin ET, Bhat TN, Liu B, Pattabiraman N, Erickson JW. Baldwin ET, et al. Among authors: erickson jw. Nat Struct Biol. 1995 Mar;2(3):244-9. doi: 10.1038/nsb0395-244. Nat Struct Biol. 1995. PMID: 7773792

10

Unsymmetric nonpeptidic HIV protease inhibitors containing anthranilamide as a P2' ligand.

Randad RS, Lubkowska L, Eissenstat MA, Gulnik SV, Yu B, Bhat TN, Clanton DJ, House T, Stinson SF, Erickson JW. Randad RS, et al. Among authors: erickson jw. Bioorg Med Chem Lett. 1998 Dec 15;8(24):3537-42. doi: 10.1016/s0960-894x(98)00657-x. Bioorg Med Chem Lett. 1998. PMID: 9934467

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

177 results

Search Page